- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- KRAS positive
- PR positive
- PR negative
- ER negative
- BRAF positive
- EGFR negative
- PD-L1 negative
- CD19 positive
- IDH positive
- HLA-A positive
- p16 positive
- ALK negative
- ALK positive
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- HLA positive
- MET positive
- IDH negative
- ROS1 positive
- TP53 positive
- MYC positive
- MSI-H positive
- FLT3 positive
- HLA negative
- p16 negative
- HR positive
- ROS1 negative
- BRAF negative
- PALB2 positive
- NRAS positive
- RB1 negative
- RB1 positive
- HLA-A negative
- dMMR positive
- HPV positive
- PIK3CA positive
- NF1 positive
- BRCA positive
- RET positive
- CD22 positive
- MET negative
- RAS positive
- BCL2 positive
- NTRK positive
- MGMT negative
- ATM positive
- BCL6 positive
- HPV negative
- CD30 positive
- ARID1A positive
- KRAS negative
- MMR positive
- anti-dsDNA positive
- BCR-ABL1 positive
- KIT positive
- Philadelphia chromosome positive
- ANA positive
- CCND1 positive
- CFTR positive
- HRAS positive
- MGMT positive
- MLH1 positive
- MSH6 positive
- NPM1 positive
- CD123 positive
- MSH2 positive
- PD-1 positive
- PMS2 positive
- PTEN positive
- RAS negative
- ctDNA positive
- CD33 positive
- CHEK2 positive
- FGFR2 positive
- KMT2A positive
- RAD51 positive
- BRIP1 positive
- HBV DNA negative
- HbSS positive
- MTAP positive
- NTRK1 positive
- RET negative
- FGFR3 positive
- HBsAg positive
- MSI positive
- MSS positive
- PD-1 negative
- anti-Sm positive
- AR positive
- ASXL1 positive
- BRCA negative
- CDK4 positive
- CLDN18.2 positive
- FGFR positive
- GPC3 positive
- HBV DNA positive
- HBsAg negative
- MMR negative
- MSI negative
- MSI-H negative
- NF2 positive
- NRAS negative
- RUNX1 positive
- STK11 positive
- TP53 negative
- p53 positive
- t(11;14) positive
- CD3 positive
- FANCA positive
- HPV16 positive
- MSS negative
- NTRK negative
- RAD51C positive
- BCR-ABL positive
- CD19 negative
- CD4 positive
- DMD positive
- EZH2 positive
- FLT3 negative
- HR negative
- JAK2 positive
- PDGFRA positive
- RAD51D positive
- RAF positive
- SMARCA4 positive
- SMN1 positive
- T790M positive
- ZnT8 positive
- dMMR negative
- ABCA4 positive
- APC positive
- BAP1 positive
- BARD1 positive
- BRCA1 negative
- BRCA2 negative
- CCNE1 positive
- CD4 count positive
- CD5 positive
- CD70 positive
- CDK12 positive
- DLL3 positive
- Del(17p) positive
- EBV positive
- EPCAM positive
- FMR1 positive
- GATA2 positive
- GRN positive
- HBcAb negative
- IA-2 positive
- Ki-67 positive
- MECP2 positive
- NF1 negative
- PTEN negative
- PTPN11 positive
- Ph positive
- RAD54L positive
- RF positive
- TERT positive
- TROP2 positive
- pMMR positive
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- \-7 positive
- AKT1 positive
- APOE ε4 positive
- APOL1 positive
- B7-H3 positive
- CD38 positive
- CDK6 positive
- CEA positive
- CHEK1 positive
- CLDN6 positive
- COL7A1 positive
- DMPK positive
- DNMT3A positive
- ER or PR positive
- FANCL positive
- FRα positive
- H3K27M positive
- HBB positive
- HBcAb positive
- HRD positive
- HbSC positive
- HbSβ0-thalassemia positive
- L858R positive
- MDM2 positive
- MLH1 negative
- MLL rearrangement positive
- MSH2 negative
- MSH6 negative
- NBN positive
- PIK3CA negative
- PMS2 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Activity Modification
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Alectinib for ALK
- Allogeneic Hematopoietic Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplant using Bone Marrow, Peripheral Blood, or Umbilical Cord Stem Cells
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
12782 trials
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares shorter chemo-immunotherapy without anthracyclines to usual chemo-immunotherapy to treat early-stage triple negative breast cancer. Drugs used to stop cancer cells from growing/dividing & kill them, plus an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a combination of two drugs to see if they're better than one drug at preventing breast cancer from coming back in patients with high risk, HER2 positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test new targeted cancer therapies against standard of care therapy in order to find more effective treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Cutaneous Melanoma trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying how well paclitaxel, trastuzumab, and pertuzumab work in eliminating chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying a combination of drugs as a possible treatment for rare genitourinary tumors.
Efficacy & Safety Awards
No Placebo-Only Group
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if ubrogepant is safe and effective for young people with migraines. Ubrogepant is a medication taken by mouth to treat migraine headaches. It works by blocking a protein in the brain that causes migraine pain. The study focuses on children and adolescents who suffer from migraines.
Efficacy & Safety Awards
Pivotal Trial
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.
Efficacy & Safety Awards
Pivotal Trial
Hutchinson, KS (<50 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the effectiveness and safety of a drug called amlitelimab in adults with non-responsive celiac disease who are on a gluten-free diet. The study will compare amlit
Wichita, KS (<50 mi)
Recruiting
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Efficacy & Safety Awards
Pivotal Trial
Verified Trial Data
No Placebo-Only Group
Get notified when new Migraine trials are postedWe'll send you an email whenever new trials are posted
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to study the safety and effectiveness of a new drug called ubrogepant in treating menstrual migraines. Menstrual migraines are headaches that occur before, during, or after
Efficacy & Safety Awards
Pivotal Trial
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50